From GlobeNewswire: 2024-03-28 16:30:00

Pyxis Oncology, Inc. granted restricted stock units and stock options to a newly hired employee, totaling 39,680 shares and 49,600 shares respectively. This was done under the 2022 Inducement Plan and will vest over four years, with 25% vesting on the first anniversary. The stock options have a $4.26 exercise price and a ten-year term.

Pyxis Oncology is a clinical stage company developing next generation cancer therapeutics targeting difficult-to-treat cancers. Their lead candidates, PYX-201 and PYX-106, are in ongoing Phase 1 clinical studies and aim to kill tumor cells and address cancer pathologies. Visit their website for more information or follow them on social media.



Read more at GlobeNewswire: Pyxis Oncology Reports Inducement Grants Under Nasdaq